$100m-$499m

Passage Bio follows $116m series A trajectory
Passage Bio will develop therapies for diseases affecting the central nervous system based on research by James Wilson at Penn, after raising almost $116m in a series A round.
Haihe Biopharma greets CAS to raise cash
Chinese Academy of Sciences invested in a round that will be used to take Haihe's anti-tumour therapies further down the clinical path.
ClearMotion rides investor interest to raise $115m
Microsoft, Bridgestone and Qualcomm all contributed to a series D round for MIT spinout ClearMotion, which emerged from stealth earlier last year with $130m in funding.
Tuspark identifies 4Paradigm in $145m series C
4Paradigm has now won backing from Tsinghua University Science Park for its technology, which helps clients build AI apps for purposes including financial services.
Poynt takes $100m series C payment
Backed by Stanford-Start X Fund and a trio of corporates, Poynt has now received more than $128m in total for its payment processing terminal and software business.
Amgen inserts $66m into Oxford Nanopore
Oxford Nanopore has secured $66m from Amgen, after the latter’s subsidiary Decode Genetics used the spinout’s technology to sequence hundreds of human genomes.
Atreca carries on funding streak
Allogene tallies up $120m
The cancer therapy developer has secured $120m in a convertible note offering featuring the University of California office of the chief investment officer.

Other News

Pfizer coughs up funding for Biontech
Biontech, an immunotherapy spinout of Johannes Gutenberg University Mainz, has received an undisclosed amount of equity funding as part of a collaboration deal that could reach $425m.
Big deal: Ambys arrives at $140m investment
Ambys Medicines has raised $60m in a series A round backed by Takeda and signed a strategic partnership agreement with the corporate worth $80m.
Ascentage tends to $150m series C
Ascentage, based on research at University of Michigan, has increased its total funding to more than $240m after closing a $150m series C round.
Investors take another slice of Lime
The Stanford-StartX Fund-backed electric scooter and bike rental service has raised $335m in a GV-led round that also included Uber.
Precision proves effective to close $110m series B
Duke Management Company and Osage University Partners have invested in the genome editing technology spinout from Duke University.

Editor's Picks

Big deal: Ambys arrives at $140m investment
Ambys Medicines has raised $60m in a series A round backed by Takeda and signed a strategic partnership agreement with the corporate worth $80m.
Immunocore smashes European biotech records
Immunotherapy firm Immunocore, which started life at Oxford University, raises the largest biotech round in European history.
test reg

Login